Efficacy and safety analysis of sugemalimab as first-line treatment for non-small cell lung cancer
LIU Fen
YIN Gui-sen
PAN Yong
YUAN Xia
LI Jin-lan
Abstract：Objective:To analyze the efficacy and safety of sugemalimab as first-line treatment for non-small cell lung cancer(NSCLC)based on real-world data and provide guidance for its rational clinical application.Methods:The clinical data of NSCLC patients hospitalized at a specialized cancer hospital from June 2022 to December 2024 and receiving first-line sugemalimab treatment were retrospectively collected.Statistical analyses were performed on efficacy,safety profiles,and influencing factors.Results:Among 81 NSCLC patients treated with sugemalimab,the median progression-free survival(PFS)was 13.6 months(10.6-NA,95%CI),with an objective response rate(ORR)of 58.0%and a disease control rate(DCR)of 95.0%.Patients with lung adenocarcinoma exhibited longer PFS compared to those with squamous cell carcinoma(17.2 vs 11.3 months,P=0.036).The incidence of all-grade adverse drug reactions(ADRs)was33.3%,with grade 3～4 ADRs occurring in 7.6%of patients.No grade 5 ADRs were observed.Myelosuppression was the most common ADR across all grades and severe cases.COX regression analysis identified pathological type,metastatic sites,and pre-treatment albumin levels as potential prognostic factors.Conclusion:Sugemalimab demonstrates favorable efficacy and safety as a first-line treatment for NSCLC in real-world clinical practice.
Keywords：real-world studysugemalimabnon-small cell lung cancer
Publication Date：2026-07-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 1553-1558 )